Ethical Issues

Level 2

  • 1

    Module 1: Ethical committees and approval processes

    • slide 2

    • slide 3

    • slide 4

    • slide 5

    • slide 6

    • slide 7_1

    • slide 8_1

    • slide 9_1

    • slide 10_1

    • slide 11

    • Knowledge Checkpoints 01

    • slide 12_1

    • slide 13_1

    • slide 14_2

    • slide 15

    • slide 16_1

    • slide 17_2

    • slide 18_1

    • Knowledge Checkpoints 02

    • slide 19_1

    • slide 20_1

    • slide 21_1

    • slide 22_2

    • slide 23_1

    • Knowledge Checkpoints 03

    • slide 24_1
  • 2

    Subject information and Consent

    • slide 2

    • slide 3

    • slide 4

    • slide 5

    • slide 6

    • slide 7

    • slide 8

    • slide 9

    • slide 10

    • slide 11

    • Knowledge Checkpoints 01

    • slide 12

    • slide 13

    • slide 14

    • slide 15

    • slide 16

    • Knowledge Checkpoints 02

    • slide 17

    • slide 18

    • slide 19

    • slide 20

    • Knowledge Checkpoints 03

    • slide 21
  • 3

    Module 3: Liability, Indemnity and Compensation

    • slide 2

    • slide 3_2

    • slide 4

    • slide 5_1

    • slide 6

    • Knowledge Checkpoints 01

    • slide 7

    • Knowledge Checkpoints 02

    • slide 8_1

    • slide 9_2

    • slide 10

Instructor

Chief Operating Officer

Dr Tina Barton

Dr. Tina Barton, Chief Operating Officer of eMQT, is a drug development specialist with over 40 years’ experience, working in partnership to lead for success as a customer-focused senior leader. During this time Dr. Barton has invested in training for the future – through team leadership, individual mentoring and training thereby sharing knowledge and developing professionals. Through her role at the Institute of Clinical Research she continues to support and lead training activities. With a passion for transformation, Dr. Barton drove the embracement of Central Eastern European countries and now is focused on the inclusion of Sub-Saharan Africa into clinical development – bringing the miracle of development of new medicines to emerging markets and new patients. Dr. Barton holds a BSc, PhD and MBA alongside over 50 academic publications and is an Honorary Fellow, and Board Member of the Institute of Clinical Research.